Occurrence of Hepoxilins and Trioxilins in Psoriatic Lesions  by Antón, Rosa et al.
REGULAR ARTICLES
Occurrence of Hepoxilins and Trioxilins in Psoriatic Lesions
Rosa Anto´n, Luı´s Puig,* Teresa Esgleyes,* Josep Marı´a de Moragas,* and Luı´s Vila
Laboratory of Inflammation Mediators, Institute of Research, Barcelona, Spain; *Dermatology Department of Santa Creu i Sant Pau Hospital, Barcelona, Spain
We recently found that normal human epidermis pro-
duces relatively high amounts of hepoxilins and trioxilins
in vitro. Therefore, the aim of this study was to demon-
strate the presence of these compounds in psoriatic
lesions. Extracts from scales of patients with chronic
stable plaque psoriasis were analyzed by a combination
of high performance liquid chromatography and gas
chromatography-mass spectrometry techniques. We
found that the levels of hepoxilin B3 were more than
16-fold higher in psoriatic scales than in normal epidermis
(3.2 K 2.3 and < 0.2 ng per mg, respectively), whereas
hepoxilin A3 was not detected in any sample. Trioxilins
were semiquantitated and referred to 12-hydroxyeicosa-
tetraenoic acid, ratios of trioxilins A3 and B3 12-
hydroxyeicosatetraenoic acid in psoriatic lesions were
Altered arachidonic acid (AA) metabolism is a typicalfeature of psoriasis (Hammarstro¨m et al, 1975; Campet al, 1983; Kragballe et al, 1986; Vila et al, 1991), andAA derived compounds are involved in its patho-physiology and in other dermatoses (Soter et al, 1983;
Chan et al, 1985; Ruzicka and Burg, 1987; Waldman et al, 1989). 12-
Lipoxygenase (12-LO) is the major AA oxygenation enzyme in
epidermal cells with total product formation generally exceeding
cyclooxygenase activity (Holtzman et al, 1989; Sola´ et al, 1992). The
most abundant eicosanoid found in psoriatic lesions and produced
by preparations of fresh human epidermis is 12-hydroxy-5,8,10,14-
eicosatetraenoic acid (12-HETE) (Hammarstro¨m et al, 1975; Camp
et al, 1983; Fogh et al, 1987; Sola´ et al, 1992). 12-HETE is formed by
the 12-LO catalyzed peroxidation of AA at C12. Platelet type 12-LO
has been found to be the predominant isoenzyme expressed in human
and murine skin epidermis (Takahashi et al, 1993; Hussain et al, 1994;
Krieg et al, 1995), and an ‘‘epidermal’’ type 12-LO that functionally
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0.65 K 0.23 and 0.32 6 0.28, respectively, and they were
not detected in normal epidermis. The presence of a great
amount of trioxilin A3 strongly suggests that hepoxilin A3
was present in psoriatic lesions and it was totally degraded
to trioxilin A3 during the analysis procedure. Our results
demonstrate that hepoxilins and trioxilins are produced
by human skin in vivo and that the levels of these
compounds are increased in psoriasis. The reported bio-
logic activities of hepoxilins indicate that they could
amplify and maintain the inflammatory response. Our
results reinforce the idea that these compounds could
play a role as mediators in the inflammatory response in
skin, particularly in psoriasis. Key words: arachidonic acid/
eicosanoid/psoriasis/12-lipoxygenase. J Invest Dermatol 110:
303–310, 1998
resembles the platelet type 12-LO is also present in murine epidermis
(Van Dijk et al, 1995; Funk et al, 1996; Kinzig et al, 1997). The
initial product of any LO is a hydroperoxide with a predominant S
configuration (Hamberg and Samuelsson, 1974; Nugteren, 1975).
Hydroperoxide-eicosatetraenoic acids (HPETE) are reduced to the
corresponding HETE by peroxidases. 12(S)-HPETE has been reported
to undergo further types of transformations to form epoxy-hydroxy
acids and trihydroxy acids in several cell types and tissues. It has been
reported that 12-HPETE can be transformed into 8-hydroxy-11,12-
epoxy-5,9,14-eicosatrienoic acid and 10-hydroxy-11,12-epoxy-5,8,14-
eicosatrienoic acid, termed hepoxilin A3 (HxA3) and hepoxilin B3
(HxB3), respectively, which can be enzymatically and nonenzymatically
transformed into 8,11,12-trihydroxy-5,9,14-eicosatrienoic acid and
10,11,12-trihydroxy-5,8,14-eicosatrienoic acid, termed trioxilin A3
(TrXA3) and trioxilin B3 (TrXB3), respectively (reviewed in Pace-
Asciak et al, 1995a, b).
We have recently reported that normal human epidermis produces –
in addition to 12-HETE – HxA3, HxB3, TrXA3, TrXB3, 8,9,12-
trihydroxyeicosatrienoic acid (8,9,12-THETrE), and 12-oxo-eicosate-
traenoic acid from exogenous AA (Anto´n et al, 1995). Some of the
reported biologic activities of these compounds suggest their role as
inflammatory mediators in skin (Dho et al, 1990; Laneuville et al, 1991;
Nigam et al, 1993; Reynaud et al, 1996; Wang et al, 1996). With the
exception of 12-HETE, the presence of 12-LO derived eicosanoids
under pathophysiologic situations has not been reported to date. All
this prompted us to determine the presence of hepoxilins (HX) and
trioxilins (TrX) in psoriatic lesions.
MATERIALS AND METHODS
Materials Hydroxyoctadecadienoic acid (HODE) and HETE were from
Cayman (Ann Arbor, MI). Authentic 8(R,S)-hydroxy-11(S),12(S)-epoxy-
5,9,14,-eicosatrienoic acid [(6)HxA3] and 10(R,S)-hydroxy-11(S),12(S)-epoxy-
5,8,14-eicosatrienoic acid [(6)HxB3] were from Cascade Biochem (Berkshire,
U.K.). Butyrylcholine esterase from horse serum was from Sigma (St. Louis,
304 ANTO´N ET AL THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
MO). [18O]-labeled water (95% 18O) was from Cambridge Isotope Laboratories
(Andover, MA). Sep-Pak C-18 silica cartridges were from Waters Millipore
(Milford, MA). All high performance liquid chromotography (HPLC) solvents
were supplied by Scharlau (Barcelona, Spain).
Recovery of normal human epidermis fragments and scales from
psoriatic patients Epidermis was isolated from skin using the Liu and Karasek
technique (Liu and Karasek, 1978). Fragments of epidermis, obtained as
described previously (Anto´n et al, 1995), were stored in methanol at –80°C
under a N2 atmosphere until the analysis of eicosanoid and octadecanoid
basal levels.
Scales from untreated patients with chronic stable plaque psoriasis involving
more than 10% of body surface, were removed by scraping with a surgical
blade and stored in methanol at –80°C under a N2 atmosphere until analysis
of eicosanoids and octadecanoids.
Preparation of internal standards Labeled internal standards were
prepared as described by Lehman et al (1992) with small modifications. Briefly,
18O-labeled HODE, HETE, and HxB3 were prepared by addition of 50 µl
[18O]-H2O containing butyrylcholine esterase (500 units per 225 µl [18O]-
H2O) to 5 µl of a mixture containing 7 µg each of 9-HODE, 13-HODE, 12-
HETE, 15-HETE, and 5-HETE, or to 13 µg of HxB3, dissolved in ethanol.
The reactions were allowed to proceed during 7 h at 37°C under continuous
agitation and, afterwards, another 50 µl of [18O]-H2O containing butyrylcholine
esterase were added and incubated for another 20 h. After incubation, the
reaction mixtures were extracted three times with two volumes of ethyl acetate.
The extracts were mixed, dried under a gentle N2 stream, redissolved in
acetonitrile, and stored at –80°C.
Standard curves Ten, 50, 200, 500, 1000, and 2000 ng of each standard
were processed as described under work-up procedure with 350 ng of
every [18O]-labeled HODE and HETE, and 600 ng of [18O]-HxB3. After
derivatization, calibration curves were made by plotting the relative response
of each compound with respect to that of the corresponding [18O]-labeled
analog versus the amount injected. For 5-HETE, the y-axis was the ratio of the
response of 5-HETE to that of the [18O]-12-HETE, for reasons given in
the Results.
Extraction of eicosanoids and octadecanoids from normal epidermis
and psoriatic scales Normal human epidermal fragments and psoriatic scales
(200 mg) were vortexed vigorously in the presence of 2 ml of methanol.
Samples were centrifuged at 5000 3 g for 5 min and the supernatant was
recovered. Pellets were washed twice with 2 ml of methanol and the extracts
were pooled. For quantitative analysis 350 ng of [18O]-9-HODE, [18O]-13-
HODE, [18O]-12-HETE, and [18O]-15-HETE, and 600 ng of [18O]-HxB3
were added to the methanolic extracts before drying under a N2 stream. They
were added after methanol extraction to avoid the action of esterases present
in biologic material. Afterwards, residues were redissolved in 10 ml sodium
acetate 0.1 M (pH 5 3.2) containing 5% ethanol and subjected to a solid phase
extraction using C18-silica cartridges according to Powell (1982). HODE,
HETE, HX, and TrX were finally eluted by flushing 20 ml of ethyl acetate
and 20 ml of methanol through the cartridge consecutively. Both extracts were
mixed, dried under N2, and redissolved in reverse phase HPLC buffer.
Reverse phase HPLC separation Separation of TrX, HX, and HODE and
HETE was accomplished by HPLC, which was performed isocratically with a
mixture of methanol/water/trifluoroacetic acid/triethylamine 75:25:0.1:0.05 at
1 ml per min in a Ultrasphere-ODS column (5 µm diameter of particle,
4.6 3 250 mm, Beckman, San Ramo´n, CA). The selected retention times to
collect the different class of compounds were 4–9 min for TrX, 14–20 min for
HX, and 22–40 min for HODE and HETE (Sola´ et al, 1992; Godessart et al,
1994; Anto´n et al, 1995).
Liquid–liquid extraction In order to concentrate the HPLC fractions, acidic
water (pH 5 3.2, acidified with hydrochloric acid) was added to achieve a
methanol:water ratio of 1:1. They were then extracted three times with half a
volume of ether:hexane (1:1). Organic extracts were mixed, dried under a N2
stream, and redissolved in acetonitrile until derivatization.
Derivatization procedure The methyl esters trimethylsilyl ethers (ME-
TMS) and hydrogenated methyl esters trimethylsilyl ethers (ME-H-TMS) were
obtained as described previously (Anto´n et al, 1995) with small modifications.
To obtain the ME derivatives 1 ml of ethereal diazomethane (Fales et al, 1973)
was added, and allowed to react for 20 min, and H2 was bubbled for 50 s to
obtain the hydrogenated derivatives. All samples were redissolved in 20 µl
acetonitrile, with 2 µl being injected into the gas chromatograph.
Figure 1. EI mass spectra of the ME-TMS derivative of the 14–20 min
HPLC fraction from psoriatic scales was consistent with the structure
of HxB3. With monitoring at m/z 73, 269, 282, and 311 a single gas
chromatography peak (CN 22.02) was obtained. The scheme of fragmentation
shows the origin of the most characteristic fragments. The spectrum was
essentially identical to that obtained from normal epidermis and authentic
(6)HxB3.
Gas chromatography-mass spectrometry (GC-MS) analysis To analyze
all samples the electron impact (EI) mode was used as previously described
(Anto´n et al, 1995). The gas chromatography column was a TRB-1 fused silica
capillary column (15 m length, 0.25 mm i.d., 0.25 µm film thickness, Tracer
analı´tica, Barcelona, Spain).
RESULTS
To investigate whether or not HX and TrX were present in normal
epidermis and in psoriatic lesions, pooled fragments of normal epidermis
and psoriatic scales were analyzed. First we processed the samples
without the addition of 18O-labeled internal standards. This was done
in order to avoid detection of HX and TrX due to the presence of
small amounts of unlabeled compounds in the samples coming from
the internal standards.
Hepoxilins are present in psoriatic lesions HX were extracted
from the HPLC fraction collected between 14 and 20 min and the
extracts were divided into two parts to produce the ME-TMS and
ME-H-TMS derivatives. The derivatives obtained were subjected to
GC-MS analysis using the full scan mode.
The presence of HxA3 in the skin samples was analyzed by
monitoring at m/z 73, 243 [carboxyl terminal fragment (CTF) from
cleavage of the C8–C9 bond], 281 [methyl terminal fragment (MTF)
from cleavage of the C7–C8 bond], and 311 (CTF from cleavage of
the C12–C13 bond). We did not find any peak with mass spectrum
compatible with the structure of HxA3 in the carbon number (CN)
range 21.0–25.0 [CN of authentic (6)HxA3 5 22.95], either in
psoriasis or in normal epidermis pools. Even when authentic (6)HxA3
was processed identically to the skin samples, no peak corresponding
to the structure of HxA3 was detected.
Monitoring suitable ions for HxB3 (m/z 73, 269, 282, and 311),
the ME-TMS derivatives of the HX fraction from both psoriatic and
normal epidermis subjected to GC-MS analysis eluted as a single peak
(CN 22.02). The EI mass spectrum had characteristic fragments
at m/z 422 (M·1, not always present), 407 ([M-15]1), 391 ([M-31]1),
311 (CTF from cleavage of the C12–C13 bond), 282 (CTF from
cleavage of the epoxide double ring at C11), 269 (CTF from cleavage
of the C10–C11 bond), and 255 (MTF from cleavage of the C9–C10
bond, not always present). This fragmentation (Fig 1) was consistent
with the structure of HxB3 and it was essentially identical to the one
obtained with authentic (6)HxB3.
Because with the gas chromatography technique used it is possible
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Figure 2. Samples from psoriatic scales showed an additional gas
chromatography peak (peak 1), which was almost undetectable in
the samples from normal epidermis, when compared with authentic
(6)HxB3. GC-MS selected ion, m/z 273, chromatograms of the ME-H-TMS
derivatives of the 14–20 min HPLC fraction from psoriatic scales pool (A), and
normal epidermis pool (B), and authentic (6)HxB3 (C). The three samples
were processed identically.
to resolve the two hydrogenated 10-hydroxy epimers of HxB3 (Anto´n
et al, 1995), the HX fraction was also catalytically hydrogenated before
TMS derivatization.
To analyze HxB3 in psoriatic lesions the fragments monitored in the
hydrogenated samples were m/z 73, 257, 273, and 287. Figure 2
shows typical m/z 273 selected ion gas chromatograms obtained from
a psoriatic scales pool, a pool of normal epidermal fragments and
authentic 10(R,S)-hydroxy-11(S),12(S)-epoxy-arachidic acid [hydro-
genated (6)HxB3]. Samples from psoriatic patients showed three peaks
with CN of 22.65, 22.80, and 22.96 (peaks 1, 2, and 3 in Fig 2,
respectively) that had essentially identical mass spectra consistent with
a 10-hydroxy-11,12-epoxy-arachidic acid structure (Fig 3). Signi-
ficant fragments were seen at m/z 428 (M·1, not always present), 413
[(M-15)1], 287 (cleavage of the epoxide double ring), 273 (CTF of
α-cleavage at C10), and 257 (MTF from cleavage of the C9–C10
bond). The ME-H-TMS derivative of authentic (6)HxB3 yielded
only two peaks with the same carbon numbers and mass spectra as
peaks 2 and 3 of the psoriatic samples. Although in samples from psoriatic
lesions peak 1 was the highest, this peak was almost undetectable in
samples from normal epidermis (Fig 2B). In addition, peaks correspond-
ing to the hydrogenolysis products, 10,11-dihydroxy-arachidic acid,
were also detected in psoriatic lesions, normal skin, and authentic
(6)HxB3 samples (peaks 4 and 5 in Fig 2). Based on these results we
concluded that not only were the two 10-hydroxy epimers of HxB3
(peaks 2 and 3 in Fig 2) present in psoriatic lesions, but another isomer
was also present (peak 1 in Fig 2), the possible identity of which will
be discussed later.
Figure 3. Mass spectra of the compounds corresponding to peaks 1, 2,
and 3 in Fig 2 are consistent with the structure of hydrogenated HxB3.
The figure shows the EI mass spectrum of peak 2 from psoriatic scales; spectra
of peaks 1 and 3 being essentially identical. Peaks 3 and 4 corresponded to the
hydrogenolysis products of HxB3: 10,11-dihydroxy-arachidic acid.
Trioxilins are present in psoriatic lesions To explore the presence
of TrX in skin samples, they were extracted from the 4–9 min HPLC
fractions from normal epidermis and psoriatic scales and the extracts
were divided into two parts to synthesize the ME-TMS and ME-H-
TMS derivatives of TrX. Then, the TrX fraction derivatives were
subjected to GC-MS analysis, performed using the full scan mode.
The ME-TMS derivatives of trioxilins would come out at m/z 213
(corresponding to the MTF from cleavage of the C11–C12 bond,
which indicates the presence of a hydroxyl group at C12) and 243
(corresponding to the CTF from cleavage of the C8–C9 bond, which
indicates the presence of a hydroxyl group at C8), for both TrXA3
and 8,9,12-THETrE, and at m/z 269 (corresponding to the CTF from
cleavage of the C10–C11 bond, which indicates the presence of a
hydroxyl group at C10) for TrXB3. Single ion chromatograms from
psoriatic samples are represented in Fig 4, and the chromatographic
and MS data are summarized in Table I. The three peaks monitoring
at m/z 213 (peaks 1, 3, and 6 in Fig 4) showed essentially identical
mass spectra, with significant fragments at m/z 569 ([M-15]1), 479
[loss of TMS as (CH3)3 SiOH (TMSOH) from the fragment at m/z
(569)], 473 (CTF from cleavage of the C12–C13 bond), 463 (loss of
TMSOH from the fragment [M-31]1), 444 (443 1 H, MTF from
cleavage of the C7–C8 bond), 383 (loss of TMSOH from the fragment
at m/z 473), 371 (CTF corresponding to cleavage of the C11–C12
bond), 353 (443-TMSOH), 315 (MTF corresponding to cleavage of the
C10–C11 bond), 281 (371-TMSOH), 243 (second most significative
abundant fragment), and 213 (base peak). This fragmentation was
consistent with the structure of TrXA3 (Jones et al, 1978; Bryant and
Bailey, 1979; German and Kinsella, 1986) (Fig 5). The detection of
three gas chromatography peaks indicates the presence of at least three
diastereoisomers of TrXA3 in the samples from psoriatic samples. The
two gas chromatography peaks monitoring at m/z 269 (peaks 2 and 4
of Fig 4) had similar mass spectra, with ions at m/z 569 ([M-15]1),
479, 473, 463, 383, 371 (CTF corresponding to cleavage of the C11–
C12 bond), 315 (MTF from cleavage of the C10–C11 bond), 281,
269 (base peak), 225 (the second most abundant ion that likely arises
from the loss of TMSOH of fragment m/z 315), and 213. This
fragmentation was consistent with the TrXB3 structure (German
and Kinsella, 1986) present in psoriatic samples at least as two
diastereoisomeric forms (Fig 5). Peak 5 showed significant ions at m/
z 569, 479, 473, 463, 444, 383, 353, 341 (MTF corresponding to
cleavage of the C8–C9 bond), 243 (base peak), and 213 (second most
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signified abundant fragment). This fragmentation was consistent with
the structure of 8,9,12-THETrE (Fig 5). The mass spectrum of peak
2 showed signified additional fragments at m/z 353 and 341 and a
relative abundant ion at m/z 243, indicating that its identity actually
consisted of a mixture of TrXB3 and 8,9,12-THETrE (Table II). No
trioxilins were detected in normal epidermal fragments.
For additional support of the structural assignment of the triols, the
TrX fraction was subjected to catalytic hydrogenation and the ME-H-
TMS derivatives were analyzed by full scan GC-MS and monitoring
specific ions for the different expected hydroxyl group positions. The
unresolved ME-H-TMS derivatives of trihydroxy acids in the total
ion chromatogram were deconvoluted by monitoring at m/z 255
(specific for hydrogenated 8,9,12-THETrE), m/z 273 (specific for
hydrogenated TrXB3), and m/z 285 (base ion of hydrogenated TrXA3).
Chromatograms monitoring at m/z 255 and 285 ions of samples
corresponding to the TrX fraction from psoriatic scales showed two
Figure 4. Different isomers of TrXA3, TrXB3, and 8,9,12-THETrE are
present in psoriatic scales. GC-MS selected ion chromatograms of ions
characteristic of the ME-TMS derivatives of the HPLC fraction 4–9 min (TrX-
fraction) from psoriatic scales. Monitoring at m/z 213, 269 and 243 was
performed to visualize the isomers of TrXA3 (A), TrXB3 (B), and 8,9,12-
THETrE (C), respectively. Gas chromatography and mass spectra data are
shown in Table I.
Table I. Gas chromatography and mass spectral data for the ME-TMS derivatives of the trihydroxy compounds present in the
4–9 min HPLC fraction are consistent with the presence of TrX in psoriatic scalesa
Compound CNb Diagnostic mass spectral ions (m/z) Peak number in Fig 4
TrXA3 (TrXB3)
c 23.611 569, 479, 473, 463, 444, 383, 371, 353, 315, 1
281, (269), 243,d 213e
TrXB3 (8,9,12-THETrE) 23.643 569, 479, 473, 463, (444), 383, 371, (353), 2
(341), 315, 281, 269, (243), 225, 213
TrXA3 (TrXB3) 23.702 569, 479, 473, 463, 444, 383, 371, 353, 315, 3
281, (269), 243, 213
TrXB3 (8,9,12-THETrE) 23.715 569, 479, 473, 463, (444), 383, 371, (353), 4
(341), 315, 281, 269, (243), 225, 213
8,9,12-THETrE (TrXA3) 23.805 569, 479, 473, 463, 444, 383, 353, 341, 5
(315), 243, 213
TrXA3 23.850 569, 479, 473, 463, 444, 383, 371, 353, 315, 6
281, 243, 213
aExtracts of a pool of scales were chromatographied by reverse phase HPLC. Then, the fraction corresponding to elution of TrX was collected, derivatized, and analyzed by GC-MS
in the EI mode. Gas chromatography chromatograms and fragmentation schemes are shown in Figs 4 and 5, respectively.
bCN, carbon number.
cCompounds in parentheses are those whose specific ions (also in parentheses) are present in minor abundance in the mass spectrum.
dThe most abundant ions are highlighted.
eBase ions are underlined.
peaks with CN of 24.47 and 24.67 (peaks 1 and 2 in Fig 6,
respectively) and essentially identical mass spectra. Significant fragments
were observed at m/z 375 (CTF from C11–C12 bond cleavage), 317
(MTF from C10–C11 bond cleavage), 285 (base peak, loss of TMSOH
from the m/z 375 fragment), 245 (CTF from C8–C9 bond cleavage),
and 215 (MTF from C11–C12 bond cleavage). This fragmentation
was consistent with the structure of the ME-H-TMS of TrXA3 and
similar to those obtained by other authors (Jones et al, 1978). These
two peaks contained additional ions at m/z 345 (MTF from C8–C9
bond cleavage) and 255 (loss of TMSOH from the m/z 345 fragment)
that are consistent with the structure of the ME-H-TMS derivative of
the 8,9,12-THETrE (Anto´n et al, 1995). The spectra and the fragmenta-
tion schemes of the aforementioned compounds are depicted in Fig 7.
These results indicated that peaks 1 and 2 in Fig 6 were a mixture of
the ME-H-TMS derivatives of the TrXA3 and 8,9,12-THETrE. The
relative intensity data apparently indicated that the former was the
major compound.
The chromatogram of monitoring at m/z 273 from the TrX fraction
of psoriatic scales showed two gas chromatography peaks with CN of
24.58 and 24.70 (peaks 3 and 4 in Fig 6, respectively) with essentially
identical mass spectra. Significant fragments were observed at m/z 375
(CTF from the C11–C12 bond cleavage), 317, 273 (CTF from the
C10–C11 bond cleavage), and 215 (base ion). This fragmentation was
consistent with the structure of the ME-H-TMS derivative of TrXB3
(Fig 7). We were unable to detect TrX in the hydrogenated extract
from the normal epidermis pool.
Based on HPLC and gas chromatography retention times, and on
the MS analysis, we can conclude that psoriatic lesions contain HX
and TrX.
Hepoxilins and trioxilins are elevated in psoriatic lesions In
order to compare levels of HX and TrX in psoriatic lesions with those
in normal epidermis, quantitative or semiquantitative analysis of HX,
TrX, HETE, and HODE were carried out, analyzing individual samples
instead of pools. For quantitative analysis we selected the ME-H-TMS
derivatives of HX, TrX, HETE, and HODE as the most suitable due
to their structure specific fragmentation and their high relative intensity
in the positive ion EI mode GC-MS (Lehmann et al, 1992; Guido
et al, 1993; Anto´n et al, 1995). Although single ion monitoring would
have enabled more sensitivity, we preferred the total scan mode to
assure identification. Quantitative evaluation was achieved by measuring
intensity of the specific major ion in the EI mass spectrum of each
compound (Table II). The ions in Table II chosen for analysis of
mono-hydroxy compounds and HxB3, formed by cleavage of the
C–C bond adjacent to the TMS ether group, contain the carboxyl
moiety and are therefore specific for the different positional isomers.
For TrX the fragment ions selected were specific and the major ones
originated from the cleavage of two adjacent carbons carrying TMS
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ether groups. In the case of TrXA3 and TrXB3 the selected ions also
contain the carboxyl moiety. Whereas, for 8,9,12-THETrE, the selected
ion contains the methyl moiety, because the fragment containing the
carboxyl moiety is common to 8,9,12-THTrE and TrXA3 ME-H-
TMS derivatives that coeluted in our gas chromatography system.
18O2-carboxyl labeled internal standards of HxB3 and the major
monohydroxy acids (9-HODE, 13-HODE, 12-HETE, 15-HETE)
were synthesized. As only 3.6% of authentic (6)HxB3 remained
unlabeled, this percentage was not enough to interfere with the
quantitative analysis. The yield of labeling for 9-HODE, 13-HODE,
12-HETE, and 15-HETE was high (%18O0 , 1). In addition, the
nonlabeled fraction from the internal standards was intrinsically taken
into account in the calibration curves. A low yield was obtained with
the 18O labeling of 5-HETE (%18O0 . 12) and during the manipulation
of the samples the percentage of 18O decreased notably, probably due
to the formation of the lactone intermediate between the hydroxyl at
Figure 5. Mass spectra of gas chromatography peaks of the samples
from psoriatic scales are consistent with the structures of TrXA3, TrXB3,
and 8,9,12-THETrE. Fragmentation schemes for the ME-TMS derivatives of
the triols present in the TrX-HPLC fraction from psoriatic scales (Fig 4,
Table I). The major diagnostic ions (numbers underlined) correspond to those
underlined as base ions in Table I. No TrX were detected in normal epidermis.
C5 position and the carboxyl group. Therefore, 5-HETE was evaluated
using the 18O2 12-HETE as internal standard instead of the
18O2 5-
HETE. A linear response was obtained in the range tested (1–200 ng
injected) for each compound with correlation coefficients varying
between 0.989 and 1.
18O labeling of authentic TrX was not possible because they were
not commercially available. Therefore minor HETE and TrX were
only semiquantitatively evaluated.
Table III shows the quantitative data from the analysis of psoriatic
scales and normal epidermis. As expected, we found that HETE and
HODE were present in significantly higher amounts in psoriatic lesions
Table II. Ions selected to quantitate the indicated compounds




9-HODE 259a 261 263
13-HODE 315 317 319
5-HETE 203 205 207
8-HETE 245 – –
9-HETE 259 – –
10-HETE 273 – –
11-HETE 287 – –
12-HETE 301 303 305
15-HETE 343 345 347
HxB3 273 275 277
TrXA3 285 – –
8,9,12b 255 – –
TrXB3 273 – –
aIons correspond to α-cleavage to a hydroxyl group of the ME-H-TMS derivatives.
These derivatives were the most suitable due to their structure specific fragmentation and
their high relative intensity in the EI mode GC-MS.
b8,9,12-THETrE.
Figure 6. GC-MS analysis of the hydrogenated 4–9 min HPLC fraction
confirmed the presence of different triols in psoriatic scales. EI GC-MS
selected ion chromatograms of the ME-H-TMS derivatives of the TrX HPLC
fraction from the psoriatic scale pool. The selected ions were m/z 255 for the
8,9,12-trihydroxy derivatives (A), 273 for TrXB3 (B), and 285 for TrXA3ı (C).
Mass spectra and fragmentation schemes are depicted in Fig 7.
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Figure 7. Mass spectra of gas chromatography peaks from
hydrogenated 4–9 min HPLC fraction from psoriatic scale samples
were consistent with the structures of hydrogenated TrXA3, TrXB3,
and 8,9,12-THETrE. Mass spectra and fragmentation schemes of compounds
corresponding to the peaks numbered in Fig 6. The major diagnostic ions
numbers are underlined. The peaks in which the compounds are present
are also indicated.
Table III. Levels of HX, TrX, HETE, and HODE are elevated
in psoriatic scalesa






d – 3.2 6 2.3e –
TrXA3 – nd – 0.65 6 0.23
8,9,12-THETrE – nd – 0.05 6 0.02
TrXB3 – nd – 0.32 6 0.28
12-HETE 0.8 6 0.3 1 21.3 6 12.4 1
15-HETE ,0.2d – 13.2 6 5.1 –
5-HETE ,0.2df – 1.5 6 0.3 –
8-HETE – ,0.04 – 0.32 6 0.17
9-HETE – nd – 0.11 6 0.06
10-HETE – nd – 0.07 6 0.03
11-HETE – ,0.03 – 0.11 6 0.09
9-HODE 0.5 6 0.2 – 46.6 6 41.5 –
13-HODE 0.4 6 0.2 – 98.0 6 88.9 –
aSamples were extracted with MeOH and the internal standards were added. The
extracts were then processed by solid phase extraction, purified by HPLC, and derivatized
to their ME-H-TMS derivatives previous to GC-MS analysis. Quantitation was performed
taking into account the linearity curves built with respect to the internal standards. When
standards were not available for a compound, semiquantitative evaluation of TrX, 8-
HETE, 9-HETE, 10-HETE, and 11-HETE levels was accomplished by calculating the
ratio of the areas of the corresponding gas chromatography peak to that of 12-HETE.
bThese data are semiquantitative values in terms of peak area relative to 12-HETE.
cnd, not detected.
dHxB3 was only detected on two samples of normal epidermis.
eMean 6 SD, n 5 5 in all cases.
f5-HETE was quantitated using 18O2 12-HETE as internal standard.
than in normal epidermis. HxB3 was also present and was more than
16-fold higher in psoriatic lesions than in normal epidermis (p , 0.05,
t test). TrX were not detected in normal epidermis. Apparently the
most abundant triol in the psoriatic scales was TrXA3 followed by
TrXB3, whereas 8,9,12-THETrE was present in small amounts. As
expected, 12-HETE was the most abundant HETE found in psoriatic
scales. We observed that the amount of 12-HETE was not well
correlated with those of HxB3 and TrX (data not shown).
DISCUSSION
To date, the formation of HX and TrX has been observed in several
animal and human tissues only in vitro (reviewed in Pace-Asciak et al,
1995a, b), or in vivo after a bolus injection of AA (Pace-Asciak et al,
1987). Here, we demonstrate the existence of HX and TrX in human
tissue under a pathophysiologic situation.
The fact that untransformed HxA3 was not found in the psoriatic
samples or in normal epidermis was an expected result because HxA3
is very unstable in the acidic conditions of our work-up, whereas
HxB3 is more stable (Nair and Jahnke, 1987; Pace-Asciak, 1994).
TrXA3 is formed from HxA3 nonenzymatically or enzymatically by
means of an epoxide hydrolase (Pace-Asciak et al, 1981; Pace-Asciak,
1988; Pace-Asciak and Lee, 1989). Formation of high amounts of
HxA3 in psoriatic lesions was supported by the fact that a great amount
of TrXA3 was found.
HxB3 formed from 12(S)-HPETE has a trans-configuration of the
epoxide group, determined by the configuration of the epoxide carbons
11(S),12(S) (Pace-Asciak, 1994; Reynaud et al, 1994). The hydroxyl
group is located in a chiral center at C10, hence HxB3 exists in two
diastereoisomeric forms. We reported that hydrogenated HxB3 from
normal epidermis incubated with exogenous AA yielded only one gas
chromatography peak with a MS spectrum corresponding to one of
the two possible 10-hydroxy epimers of HxB3, whereas samples from
authentic hydrogenated racemic HxB3 yielded two gas chromatography
peaks that correspond to the two epimeric forms at C10 (Anto´n et al,
1995). Unexpectedly, in addition to these two peaks, psoriatic samples
yielded a major peak with a MS spectrum also consistent with the
structure of the hydrogenated HxB3. One can speculate that, in
psoriatic lesions, the enantiomer 10(S,R)-hydroxy-11(R),12(R)-epoxy
is also present. This could be possible because the R enantiomer of
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12-HETE is more abundant than 12(S)-HETE in psoriatic lesions
(Woollard, 1986; Baer et al, 1991). In contrast, 12(S)-HETE is the
predominant enantiomer in human cell suspensions (S:R enantiomer
ratio varied between 2:1 and 8:1) (Holtzman et al, 1989), epidermal
homogenates, or fragments (S:R enantiomer ratio was µ3:1) (unpub-
lished results). Part of the 12(R)-HETE could originate from 12(R)-
HPETE; however, 10(S,R)-hydroxy-11(S),12(S)-epoxy and 10(S,R)-
hydroxy-11(R),12(R)-epoxy configurations are enantiomers, which
coelute when a nonchiral stationary phase is used, resulting in only
two peaks corresponding to the two epimers at C10. Hence, the most
probable explanation for the additional peak found in psoriatic scales
would be the presence of the diastereomers 10(S,R)-hydroxy-
11(R),12(S)-epoxy or/and 10(S,R)-hydroxy-11(S),12(R)-epoxy com-
pounds, which are cis-epoxides, in the psoriatic samples. Monooxy-
genases produce cis-epoxides (Capdevila et al, 1984, 1990), in contrast
to trans-epoxides formed by lipoxygenases (Garssen et al, 1976).
Nevertheless, monooxygenases produce epoxy-eicosatrienoic acids
instead of hydroxy-epoxy acids (Carrol et al, 1988). So, it is possible
that 10-hydroxy-cis-epoxides were formed by rearrangement of an AA
peroxide radical intermediate as a result of an auto-catalytic process
induced by free radicals, e.g., OH·, or by ONOO– formed by the
reaction of NO·, with O2·, (Rubbo et al, 1994; Laskey and Mathews,
1996). In fact, overexpression of inducible NO synthase has been
reported in psoriatic skin (Kolb-Bachofen et al, 1994; Sirsjo¨ et al, 1996).
Human heel callus is only composed by stratum corneum and is not
able to metabolize AA (Heinnecke-von Zepelin et al, 1991). In this
aspect, the stratum corneum is different from psoriatic scales, which
apparently still have active enzymes able to transform AA into HETE
(Baer et al, 1991). So, for the quantitative study we preferred to
compare psoriatic scales with normal human epidermal fragments
formed by the corneal and granular layers instead of human heel callus.
Consistent with data reported by other authors (Camp et al, 1983),
we found that the major products analyzed were octadecanoids derived
from linoleic acid, 13-HODE, and 9-HODE, through the action of
15-LO and cyclooxygenase, most likely cyclooxygenase-2 (Burrall et al,
1988; Camacho et al, 1995; Godessart et al, 1996). As expected, 12-
HETE was the major eicosanoid. We found levels of HETE and
HODE in psoriatic scales in the same order of magnitude but higher
than those reported by others (Camp et al, 1983; Fogh et al, 1989).
These differences may arise from the different analytical procedures
used, such as peak integration by optical density performed by Fogh
et al (1989) or the semiquantitation by GC-MS without taking into
account the recovery of the process as Camp et al (1983) did. We
corrected for the recovery and uncontrollable instrument variations by
adding a 18O labeled internal standard. Another reason for the differ-
ences with respect to data reported by others could be the great
variation between patients, even though our results ranged in the limits
observed by Fogh et al (1987). These authors demonstrated differences
in the content of lipoxygenase products between different layers of the
lesions in the same patient. In this sense, we worked with scales from
untreated chronic plaques, from different body areas containing only
suprapapillary epidermis.
We found that the amount of HxB3 was more than 16-fold higher
in psoriatic lesions than in normal epidermis, and the ratio of HxB3
12-HETE levels (0.15) was quite significant. It is worthwhile to
emphasize that HxB3 was present in psoriatic scales at concentrations
able to exert biologic effects (assuming a density of 1 g per ml, the
concentration of HxB3 and 12-HETE in psoriatic epidermis was 10 µM
and 66 µM, respectively) (Pace-Asciak, 1994). Apparently, the most
abundant TrX in the psoriatic scales was TrXA3 followed by TrXB3,
although 8,9,12-THETrE was present in small amounts. This could
be explained by the conversion of HxA3 into TrXA3 in the tissue
and/or during the analytical procedure. In fact, HxA3 was converted
into TrXA3 because we did not detect it. So, the TrXA3 measured
was actually the sum of the HxA3 and TrXA3 present in the samples.
An interesting observation is that the total amount of triols in psoriatic
lesions was similar to that of 12-HETE in terms of peak area.
Support for the potential role of HX in the pathogenesis of
inflammatory skin diseases, in particular in psoriasis, includes their
potent action on plasma permeability when injected subcutaneously
(Laneuville et al, 1991; Wang et al, 1996), a specific receptor dependent
(Nigam et al, 1993; Reynaud et al, 1996) induction of Ca21 mobilization
from endogenous sources (Dho et al, 1990; Laneuville et al, 1993),
release of AA and diacylglycerol (Nigam et al, 1993) in human
neutrophils, and the detection of considerable amounts in psoriatic
lesions. Interestingly, whereas (6)HxA3 and (6)HxB3 are both active
in enhancing the bradykinin evoked permeability in skin, only 10(R)-
HxB3 (which probably is the epimer synthesized by normal epidermis;
Anto´n et al, 1995) stereospecifically enhances the vascular permeability
evoked by intradermal injection of platelet activating factor (Wang
et al, 1996).
As a result, Ca21 dependent phospholipase A2 could be activated
and the translocation of 5-LO would lead to the release of other
mediators such as leukotrienes. It has also been observed that a Ca21
pulse, elicited by IL-8, promotes epidermal cell proliferation (Tuschil
et al, 1992). The effect of HxA3 on Ca
21 mobilization has been
demonstrated in neutrophils and whether or not this effect also occurs
in epidermal cells should be the subject of further investigations.
In summary, the presence of biologically active amounts of HX and
TrX in psoriatic lesions suggests that these compounds could play a
role as modulators of the inflammatory response on skin. More research
focused on the biologic role on dermatoses and the biochemical
pathways involved in the biosynthesis of HX in human epidermis is
under progress in our laboratory.
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